The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
A U.S. Navy admiral who oversees military operations in Latin America handed off command responsibilities Friday as scrutiny ...
House Republicans unveiled a narrow health care package on Friday that does not extend soon-to-expire enhanced Affordable Care Act subsidies — the latest sign that Congress is unlikely to avert ...
A Toronto-area lawyer — who allegedly counselled fugitive Ryan Wedding to murder an FBI witness — risks being assassinated if ...
Adm. Alvin Holsey has retired one year into a posting that typically lasts three to four years and transferred leadership ...
DelveInsight’s “IgG4-related Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...
Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...
Venezuelan leader Nicolás Maduro says escalating pressure from the US comes down to one thing: Washington wants to grab the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback